General
Preferred name
Cenobamate
Synonyms
Ontozry ()
Cenobamato ()
YKP-3089 ()
YKP3089 ()
Xcopri ()
P&D ID
PD077620
CAS
913088-80-9
Tags
available
drug
Approved by
FDA
EMA
First approval
2020
2019
Drug indication
Epilepsy
Complex partial seizure
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cenobamate (YKP-3089) is an oral anti-epilepsy drug. Pharmacological evidence shows that it acts as a positive allosteric modulator (PAM) at GABAA channels and as an inhibitor of the INaP current via voltage-gated sodium channels in isolated rat hippocampal neurons.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
NCATS Inxight Approved Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
267.05
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
1.16
TPSA
95.92
Fraction CSP3
0.2
Chiral centers
1.0
Largest ring
6.0
QED
0.9
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
GABA receptor modulator, voltage-gated sodium channel blocker
Source data
